Jan Braess

6.9k total citations
98 papers, 2.4k citations indexed

About

Jan Braess is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jan Braess has authored 98 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Hematology, 42 papers in Molecular Biology and 27 papers in Oncology. Recurrent topics in Jan Braess's work include Acute Myeloid Leukemia Research (66 papers), Acute Lymphoblastic Leukemia research (21 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). Jan Braess is often cited by papers focused on Acute Myeloid Leukemia Research (66 papers), Acute Lymphoblastic Leukemia research (21 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). Jan Braess collaborates with scholars based in Germany, New Zealand and United States. Jan Braess's co-authors include Wolfgang Hiddemann, Karsten Spiekermann, Bernhard Wörmann, Wolfgang E. Berdel, Stefan K. Bohlander, Klaus H. Metzeler, Thomas Büchner, Wolfgang Kern, Maria‐Cristina Sauerland and Annika Dufour and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jan Braess

91 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Braess Germany	27	1.8k	1.1k	540	491	409	98	2.4k
Eytan M. Stein United States	28	2.3k 1.3×	2.0k 1.7×	636 1.2×	511 1.0×	617 1.5×	203	3.4k
Agnieszka Wierzbowska Poland	22	1.5k 0.8×	1.1k 1.0×	461 0.9×	435 0.9×	483 1.2×	108	2.3k
Mario Tiribelli Italy	25	1.3k 0.7×	656 0.6×	922 1.7×	277 0.6×	610 1.5×	97	2.2k
Ralph Wäsch Germany	31	2.1k 1.2×	1.6k 1.4×	333 0.6×	324 0.7×	1.2k 3.0×	172	3.3k
Jonathan Kell United Kingdom	20	1.9k 1.1×	1.1k 1.0×	392 0.7×	683 1.4×	574 1.4×	57	2.5k
Qaiser Bashir United States	22	1.4k 0.8×	762 0.7×	273 0.5×	273 0.6×	745 1.8×	182	2.0k
Ellin Berman United States	31	2.2k 1.2×	1.2k 1.1×	992 1.8×	871 1.8×	1.2k 3.0×	99	3.8k
J Treleaven United Kingdom	28	1.1k 0.6×	397 0.3×	291 0.5×	334 0.7×	515 1.3×	71	2.0k
Deborah Berg United States	24	2.9k 1.6×	2.0k 1.7×	584 1.1×	819 1.7×	1.1k 2.8×	66	3.6k
Jeffrey L. Wolf United States	27	1.9k 1.0×	1.5k 1.3×	255 0.5×	168 0.3×	1.2k 3.0×	116	2.6k

Countries citing papers authored by Jan Braess

Since Specialization

Citations

This map shows the geographic impact of Jan Braess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Braess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Braess more than expected).

Fields of papers citing papers by Jan Braess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Braess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Braess. The network helps show where Jan Braess may publish in the future.

Co-authorship network of co-authors of Jan Braess

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Braess. A scholar is included among the top collaborators of Jan Braess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Braess. Jan Braess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gerken, Michael, et al.. (2024). How accurate is clinical prognostication by oncologists during routine practice in a general hospital and can it be improved by a specific prognosis training programme: a prospective interventional study. BMJ Open. 14(6). e081661–e081661.

Rausch, Christian, Maja Rothenberg‐Thurley, Annika Dufour, et al.. (2023). Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 37(6). 1234–1244. 45 indexed citations

Stratmann, Jan, Nikolaj Frost, Petros Christopoulos, et al.. (2023). 1405P Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany. Annals of Oncology. 34. S804–S804. 1 indexed citations

Müller, Karolina, et al.. (2023). Gender Differences in Symptom Burden, Functional Performance and Global Quality of Life of Lung Cancer Patients Receiving Inpatient versus Outpatient Treatment. Cancer Management and Research. Volume 15. 175–183. 2 indexed citations

Birndt, Sebastian, Thomas Schenk, Frank M. Brunkhorst, et al.. (2020). Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. Journal of Cancer Research and Clinical Oncology. 146(4). 1065–1077. 69 indexed citations

Kron, Anna, Richard Riedel, Sebastian Michels, et al.. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v461–v462. 6 indexed citations

Rothenberg‐Thurley, Maja, Thomas Köhnke, Nikola P. Konstandin, et al.. (2017). Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 9 indexed citations

Rothenberg‐Thurley, Maja, Susanne Amler, Dennis Göerlich, et al.. (2016). Persistence of Driver Mutations during Complete Remission Associates with Shorter Survival and Contributes to the Inferior Outcomes of Elderly Patients with Acute Myeloid Leukemia. Haematologica. 2 indexed citations

Wilhelm, Martin, Lothar Mueller, Michael Craig Miller, et al.. (2016). Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. Clinical Colorectal Cancer. 15(4). 381–388. 54 indexed citations

10.

Fiegl, Michael, Michael Unterhalt, Wolfgang Kern, et al.. (2013). Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. Leukemia. 28(5). 1001–1007. 22 indexed citations

11.

Dufour, Annika, Friederike Schneider, Eva Hoster, et al.. (2012). Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Annals of Hematology. 91(7). 1051–1063. 27 indexed citations

12.

Pfeiffer, Tim, Michael Schleuning, Jiří Mayer, et al.. (2012). Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematologica. 98(4). 518–525. 21 indexed citations

13.

Greif, Philipp A., Nikola P. Konstandin, Klaus H. Metzeler, et al.. (2012). RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 97(12). 1909–1915. 66 indexed citations

14.

Dufour, Annika, Friederike Schneider, Klaus H. Metzeler, et al.. (2009). Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome. Journal of Clinical Oncology. 28(4). 570–577. 189 indexed citations

15.

Schneider, Friederike, Eva Hoster, Michael Unterhalt, et al.. (2009). NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 113(21). 5250–5253. 48 indexed citations

16.

Heilmeier, Bernhard, Stefan K. Bohlander, Christian Buske, et al.. (2009). Moderne Leukämiediagnostikbeim Erwachsenen. DMW - Deutsche Medizinische Wochenschrift. 134(23). 1222–1226. 1 indexed citations

17.

Büchner, Thomas, Wolfgang E. Berdel, Claudia Haferlach, et al.. (2008). Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology. 27(1). 61–69. 232 indexed citations

18.

Fiegl, Michael, et al.. (2006). Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia. Leukemia Research. 31(4). 531–539. 8 indexed citations

19.

Braess, Jan, et al.. (2005). Modeling the Pharmacodynamics of Highly Schedule-Dependent Agents: Exemplified by Cytarabine-Based Regimens in Acute Myeloid Leukemia. Clinical Cancer Research. 11(20). 7415–7425. 7 indexed citations

20.

Kern, Wolfgang, Jan Braess, Hartmut Bertz, et al.. (1998). Chronic systemic aspergillosis in a patient with acute myeloid leukemia. Annals of Hematology. 76(3-4). 175–177. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact